NCT05298254 / 2021-003586-35: A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes |
|
|
| Active, not recruiting | 1/2 | 505 | Europe, Canada, US, RoW | Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2 | GlaxoSmithKline, GlaxoSmithKline Biologicals | Herpes Simplex | 07/25 | 07/25 | | |
| Recruiting | N/A | 2000 | Europe | | University Hospital, Essen | HIV Infections, Coronary Disease, Myocardial Infarction, HIV Encephalopathy, Aging, Heart Failure, Weight Gain | 10/25 | 12/25 | | |
